AETHLON MEDICAL INC (AEMD)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$5.31-7.65%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · AEMD
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
“We believe Aethlon stockholders will have a compelling opportunity to participate in the development of North Immunology’s pipeline through their ownership interest in the combined company, while al…
Stated in a supplied disclosure. Management reported: “The merger and concurrent private placement, which is expected to provide approximately $180 million in gross proceeds, are expected to position the combined company to advance the development of NOR-101, a potentially best-in-class half-life extended IL-13 x IL-18 bispecific antibody that is being developed for atopic dermatitis (“AD”) and other immune-mediated diseases.” ““We believe Aethlon stockholders will have a compelling opportunity to participate in the development of North Immunology’s pipeline through their ownership interest in the combined company, while also retaining the potential to realize value from Aethlon’s legacy assets through the contingent value rights,” said James Frakes, Chief Executive Officer of Aethlon.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“We treated the first participant in the third and final dosing cohort of our Phase 1 oncology study in Australia, and early biomarker signals from the initial cohorts support continuing evaluation o…
Stated in 2 of 2 supplied quarters. Management reported: ““We treated the first participant in the third and final dosing cohort of our Phase 1 oncology study in Australia, and early biomarker signals from the initial cohorts support continuing evaluation of the Hemopurifier.” “Key Highlights · Advanced the Australian oncology study through completion of the first two cohorts and entered the third and final dosing cohort, representing a key clinical milestone toward generating data to inform future development and dosing strategy.”
““We treated the first participant in the third and final dosing cohort of our Phase 1 oncology study in Australia, and early biomarker signals from the initial cohorts support continuing evaluation o…”
“Key Highlights · Advanced the Australian oncology study through completion of the first two cohorts and entered the third and final dosing cohort, representing a key clinical milestone toward generat…”
|| · | Operating expenses: Consolidated operating expenses for the quarter decreased 11.9% to approximately $1.6 million versus $1.8 million in the prior-year quarter, driven by lower professional fe…
Stated in 2 of 2 supplied quarters. Management reported: “|| · | Operating expenses: Consolidated operating expenses for the quarter decreased 11.9% to approximately $1.6 million versus $1.8 million in the prior-year quarter, driven by lower professional fees and reduced general and administrative and preclinical research costs.” “2 Consolidated operating expenses declined 21.9% year-over-year to approximately $7.3 million, reflecting continued expense discipline and operational efficiency while advancing the Company’s clinical and research priorities compared to $9.3 million for the fiscal year ended March 31, 2025.”
“|| · | Operating expenses: Consolidated operating expenses for the quarter decreased 11.9% to approximately $1.6 million versus $1.8 million in the prior-year quarter, driven by lower professional fe…”
“2 Consolidated operating expenses declined 21.9% year-over-year to approximately $7.3 million, reflecting continued expense discipline and operational efficiency while advancing the Company’s clinica…”
Progress the Phase 1 oncology study through dosing cohorts and evaluate Hemopurifier's safety and efficacy in cancer patients.
Secure funding via public offerings and private placements to maintain liquidity and support clinical and corporate activities.
Over the trailing year it converted 0.86x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
17 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.